Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial

Author： Mohty Mohamad   Malard Florent   Blaise Didier   Milpied Noel   Furst Sabine   Tabrizi Resa   Guillaume Thierry   Vigouroux Stéphane   El-Cheikh Jean   Delaunay Jacques   Le Gouill Steven   Moreau Philippe   Labopin Myriam   Chevallier Patrice  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|4|562-569

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.4, 2015-02, pp. : 562-569

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intravenous Busulfan: In the Conditioning Treatment of Pediatric Patients Prior to Hematopoietic Stem Cell Transplantation

By Hoy Sheridan M.   Lyseng-Williamson Katherine A.  

Pediatric Drugs, Vol. 9, Iss. 4, 2007-01 ,pp. : 271-278

Adis International

Access to resources Recommend Favorite

Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children

By  

Current Drug Metabolism, Vol. 15, Iss. 3, 2014-03 ,pp. : 251-264

Bentham Science Publishers

Access to resources Recommend Favorite

Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation

By Hassan Moustapha   Andersson Borje S  

Pharmacogenomics, Vol. 14, Iss. 1, 2013-01 ,pp. : 75-87

Future Medicine

Access to resources Recommend Favorite

Cytostatic conditioning in experimental allogeneic bone marrow transplantation: Busulfan causes less early gastrointestinal toxicity but Treosulfan results in improved immune reconstitution

By Bouazzaoui Abdellatif   Dickhöfer Sabine   Kreuz Marina   Huber Elisabeth   Holler Ernst   Wolff Daniel  

Immunopharmacology and Immunotoxicology, Vol. 36, Iss. 2, 2014-04 ,pp. : 158-164

Informa Healthcare

Access to resources Recommend Favorite

Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma

By Chen Yi-Bin   Batchelor Tracy   Li Shuli   Hochberg Ephraim   Brezina Mark   Jones Sooae   Del Rio Candice   Curtis Morgan   Ballen Karen K.   Barnes Jeffrey   Chi Andrew S.   Dietrich Jorg   Driscoll Jessica   Gertsner Elizabeth R.   Hochberg Fred   LaCasce Ann S.   McAfee Steven L.   Spitzer Thomas R.   Nayak Lakshmi   Armand Philippe  

Cancer, Vol. 121, Iss. 2, 2015-01 ,pp. : 226-233

Blackwell Publishing

Access to resources Recommend Favorite